Due to its constantly growing incidence, obesity is an increasingly serious social and
medical problem. Available data on the use of novel oral anticoagulants in morbidly obese …

Obesity is a significant cause of morbidity and mortality, and it is becoming increasingly
prevalent worldwide. Altered pharmacodynamics and pharmacokinetics of drugs in obese …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Obesity has become a major threat to health worldwide. The prevalence of obesity is rapidly
increasing, so much so that the World Health Organization has declared obesity as a global …

Introduction: There is limited efficacy and safety data for direct oral anticoagulants (DOACs)
in patients with obesity, and it has been suggested to avoid DOACs in this patient …

Extreme obesity—also referred to as severe, grade III, or morbid obesity—is defined as a
body mass index (BMI)> 40 kg/m2, and occurs in 7.7% of the adult US population. 1 This …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

The prevalence of obesity has increased substantially over recent years. Clinicians are
increasingly being challenged with making uncertain anticoagulant dosing decisions, as the …

Background: Limited clinical data exists regarding use of direct oral anticoagulants (DOACs)
in extreme obesity, specifically those≥ 140 kg or having a body mass index (BMI)≥ 50 …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …